Legal & General Group
LENZ

Legal & General Group’s LENZ Therapeutics LENZ Stock Holding History

Legal & General Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.7K Sell
8,169
-2,561
-24% -$36K ﹤0.01% 2632
2025
Q4 		$172K Sell
10,730
-33
-0.3% -$962 ﹤0.01% 2595
2025
Q3 		$501K Sell
10,763
-226
-2% -$8.31K ﹤0.01% 2447
2025
Q2 		$322K Buy
10,989
+2,247
+26% +$61.1K ﹤0.01% 2550
2025
Q1 		$225K Hold
8,742
– – ﹤0.01% 2594
2024
Q4 		$252K Buy
8,742
+7,654
+703% +$233K ﹤0.01% 2636
2024
Q3 		$25.8K Hold
1,088
– – ﹤0.01% 2948
2024
Q2 		$18.8K Buy
1,088
+706
+185% +$12.3K ﹤0.01% 3047
2024
Q1 		$8.53K Hold
382
– – ﹤0.01% 3233
2023
Q4 		$7.01K Hold
382
– – ﹤0.01% 3281
2023
Q3 		$6.64K Hold
382
– – ﹤0.01% 3336
2023
Q2 		$6.96K Buy
+382
New +$7.63K ﹤0.01% 3355
2022
Q2 		– Sell
-404
Closed -$14K – 3679
2022
Q1 		$14K Buy
404
+187
+86% +$11.7K ﹤0.01% 3328
2021
Q4 		$19K Hold
217
– – ﹤0.01% 3297
2021
Q3 		$25K Buy
+217
New +$32.1K ﹤0.01% 3200

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Legal & General Group's LENZ Position: Q1 2026 in Review

Legal & General Group reduced its LENZ Therapeutics (LENZ) stake by 24% in Q1 2026, selling an estimated $36K and leaving 8,169 shares worth $74.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2632.

Legal & General Group first reported a position in LENZ in Q3 2021 and has held it in 15 quarters since. The position peaked at $501K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Legal & General Group held 8,169 shares of LENZ Therapeutics worth $74.7K as of Q1 2026.
  • Legal & General Group sold 2,561 LENZ Therapeutics shares in Q1 2026, an estimated $36K.
  • LENZ Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2632 holding.
  • Legal & General Group first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 15 quarters since.
  • Legal & General Group's LENZ Therapeutics position peaked at $501K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.